{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T03:16:46Z","timestamp":1791170206357,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2009,7,1]],"date-time":"2009-07-01T00:00:00Z","timestamp":1246406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1016\/j.lungcan.2008.10.016","type":"journal-article","created":{"date-parts":[[2008,12,7]],"date-time":"2008-12-07T05:24:56Z","timestamp":1228627496000},"page":"80-84","source":"Crossref","is-referenced-by-count":102,"title":["Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI"],"prefix":"10.1016","volume":"65","author":[{"given":"Hyeon Gyu","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae-Won","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Do-Youn","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seock-Ah","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-You","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Seog","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Jue","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2008.10.016_bib1","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/cncr.10687","article-title":"Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: risk factors analysis","volume":"95","author":"Ceresoli","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2008.10.016_bib2","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1200\/JCO.2005.01.131","article-title":"Neoplastic meningitis","volume":"23","author":"Chamberlain","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.lungcan.2008.10.016_bib3","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/jjco\/hyg118","article-title":"Comparison of intrathecal chemotherapy for leptomeningeal carcinomatosis of a solid tumor: methotrexate alone versus methotrexate in combination with cytosine arabinoside and hydrocortisone","volume":"33","author":"Kim","year":"2003","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2008.10.016_bib4","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nrc2088","article-title":"Epidermal growth factor receptor mutations in lung cancer","volume":"7","author":"Sharma","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.lungcan.2008.10.016_bib5","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.lungcan.2008.10.016_bib6","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2005.01.388","article-title":"Predictive and prognostic Impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib","volume":"23","author":"Han","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.10.016_bib7","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/cncr.21033","article-title":"High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib","volume":"103","author":"Omuro","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2008.10.016_bib8","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1200\/JCO.2006.06.6126","article-title":"Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib","volume":"24","author":"Jackman","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2008.10.016_bib9","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/ncponc0400","article-title":"Gefitinib response of erlotinib-refractory lung cancer involving meninges-role of EGFR mutation","volume":"3","author":"Choong","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2008.10.016_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s10147-005-0558-x","article-title":"Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib","volume":"11","author":"Sakai","year":"2006","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.10.016_bib11","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1200\/JCO.2006.10.4166","article-title":"Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib","volume":"25","author":"Cho","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2008.10.016_bib12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.lungcan.2007.05.018","article-title":"Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer","volume":"58","author":"Chang","year":"2007","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2008.10.016_bib13","unstructured":"Lee DH, Kim SW, Suh C, Yoon DH, Yi EJ, Lee JS. Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment. Ann Oncol [Epub ahead of print]."},{"key":"10.1016\/j.lungcan.2008.10.016_bib14","doi-asserted-by":"crossref","first-page":"4292","DOI":"10.1200\/JCO.2002.03.100","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types","volume":"20","author":"Baselga","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2008.10.016_bib15","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1093\/annonc\/mdg250","article-title":"Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (\u2018Iressa\u2019, ZD1839) in Japanese patients with solid malignant tumors","volume":"14","author":"Nakagawa","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.lungcan.2008.10.016_bib16","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/00498250400009171","article-title":"Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man","volume":"34","author":"McKillop","year":"2004","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.lungcan.2008.10.016_bib17","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1001\/archneur.55.4.506","article-title":"Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy","volume":"55","author":"Chamberlain","year":"1998","journal-title":"Arch Neurol"},{"key":"10.1016\/j.lungcan.2008.10.016_bib18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.lungcan.2008.10.016_bib19","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","article-title":"Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain","volume":"2","author":"Pao","year":"2005","journal-title":"PLoS Med"},{"key":"10.1016\/j.lungcan.2008.10.016_bib20","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500208005552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500208005552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,23]],"date-time":"2018-12-23T16:25:01Z","timestamp":1545582301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500208005552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["S0169500208005552"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2008.10.016","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}